BioMedNewsBreaks — Astrotech Corp. (NASDAQ: ASTC) Releases Q3 202 Financial Report

Company: Astrotech Corp. (ASTC)
Category: News

Astrotech (NASDAQ: ASTC), an innovative science and technology company, is reporting its financial results for the third quarter of fiscal year 2024, for the period ended March 31, 2024. Highlights of the report include the company’s strong consolidated balance sheet showing $34.7 million in cash and liquid investments; revenue for the year-to-date coming in at $1.6 million; year-to-date gross margin increased to 45% from 37% through the third quarter of fiscal year 2024; the company’s subsidiary, 1st Detect, accepting orders for the TRACER 1000 Narcotics Trace Detector (“NTD”); the TRACER 1000 being listed in the U.S. General Services Administration (“GSA”) IT Schedule 70, meaning it can be purchased by the U.S. federal government, one of the largest buyers of goods and services in the world; the formation of a wholly owned subsidiary Pro-Control Inc., which offers the proprietary Pro-Control Maximum Value Processing and the PRO-CONTROL-1000(TM) mass spectrometer, which is designed to test, measure and increase potency, purity and weight yields in the chemical manufacturing space; and First Detect exhibiting TRACER 1000 NTD and ETD at the International Security Conference and Exposition in Las Vegas, Nevada. “We believe mass spectrometry continues to be the best technology for the detection of explosives,” said Astrotech chair, CEO and chief technology officer Thomas B. Pickens III in the press release. “We are continually expanding the product line for new applications and market channels. The introduction of the TRACER 1000 NTD, a narcotics detection instrument, is expected to extend our product into more markets including military, law enforcement and security. Also, having the 1st Detect TRACER 1000 product added to the GSA list will create even more traction for our technology in the U.S. by making it very easy for government entities to purchase our product without the lengthy budget approval needed for most procurement events. We are expanding the sales department and ramping up sales and marketing efforts in the fourth quarter, which should help maintain the momentum built in fiscal year 2024 into fiscal year 2025.”

To view the full press release, visit https://ibn.fm/7Pw47

About Astrotech Corp.

Astrotech is a mass spectrometry company that launches, manages and commercializes scalable companies based on its innovative core technology through its wholly owned subsidiaries. 1st Detect develops, manufactures and sells trace detectors for use in the security and detection market. AgLAB develops and sells chemical analyzers for use in the agriculture market. BreathTech is developing a breath-analysis tool to screen for volatile organic compounds that could indicate bodily infections and compromised conditions. Pro-Control is developing the mass spectrometry technology for use in chemical manufacturing processes. Astrotech is headquartered in Austin, Texas. For more information, please visit www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050